Pharmaceutical composition for prevention or treatment of flavivirus infectious disease

A composition and flavivirus technology, applied in the directions of antiviral agents, active ingredients of heterocyclic compounds, pharmaceutical formulations, etc., to achieve the effect of inhibiting proliferation

Pending Publication Date: 2020-12-04
LEMONEX +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, no other virus is marketed as an approved vaccine against clinically important viscera-affinity flaviviruses such as dengue, West Nile virus, Omsk hemorrhagic fever virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for prevention or treatment of flavivirus infectious disease
  • Pharmaceutical composition for prevention or treatment of flavivirus infectious disease
  • Pharmaceutical composition for prevention or treatment of flavivirus infectious disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0071] 1. Method

[0072] (1) Evaluation of cell viability

[0073] CCK-8 analysis was performed according to the manufacturer's instructions.

[0074] Before the experiment, the 10.5×10 4 cells / cm 2 and 7.0×10 4 cells / cm 2 Density of VeroE6 cells were inoculated. At 37°C, 5% CO 2 After 24 hours of incubation, montelukast was treated at serially diluted concentrations for 48 hours. Each group was treated with CCK-8 reagent at a concentration of 10% v / v and incubated for 1-4 hours under normal cell culture conditions. Quantitative analysis of colorimetric intensity changes was performed by measuring the optical density of formazan salt at 450 nm using a microplate reader ((Molecular Devices, Inc., USA). The experiment was performed three times, and the data were expressed as mean ± SEM.

[0075] (2) Experimental group of intracellular virus infection experiment

[0076] Before the experiment, the 10.5×10 4 cells / cm 2 and 7.0×10 4 cells / cm 2 Density of VeroE6 cells ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition comprising at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin, and cephalothin, which can exhibit excellent growth inhibition and killing effects on various viruses in the family Flaviviridae.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating flavivirus infection. Background technique [0002] Flaviviruses are small, enveloped, positive-sense RNA viruses, some of which currently or in the future threaten or potentially threaten human health worldwide. For example, yellow fever virus has been responsible for some bush epidemics in sub-Saharan Africa or parts of South Africa. Many yellow fever infections are not very serious, but they can cause serious and life-threatening illness. The conditions of these diseases are divided into the following two stages. The early acute phase is characterized by high fever, chills, headache, back pain, myalgia, anorexia, nausea, and vomiting. After 3 to 4 days, such symptoms disappear. In some patients, these symptoms may recur when the disease enters the so-called virulent phase (or "toxic phase"). During the toxic phase, high fever returns and may lead to shock, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7036A61K31/7008A61K31/47A61P31/14
CPCY02A50/30A61K31/47A61K31/7036A61P31/14A61K31/5415A61K31/4706A61K31/496A61K31/555A61K31/282A61K31/536A61K31/685A61K31/7048A61K31/546A61K31/402A61K31/422A61K38/14A61K38/12A61K31/7008A61K31/661C12Y203/01059
Inventor 元哲喜闵达熙
Owner LEMONEX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap